Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2948 articles with Eli Lilly and Company
-
Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients
11/18/2021
Today, Eli Lilly and Company (NYSE: LLY) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults.
-
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
-
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference
11/17/2021
Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021.
-
Three companies have posted major developments in the field of heart disease therapy.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
11/12/2021
Dicerna Pharmaceuticals, Inc. today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing collaboration.
-
Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
-
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.
-
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
-
Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19
11/2/2021
Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together.
-
Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference
11/1/2021
Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4 , 2021.
-
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
10/28/2021
Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology.
-
The decision came following negative feedback from both U.S. and European regulators.
-
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential
10/26/2021
Eli Lilly and Company announced financial results for the third quarter of 2021.
-
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round. The company focuses on developing treatments for celiac disease and other immune-related conditions.
-
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk
10/19/2021
Adults with type 2 diabetes with increased cardiovascular risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's SURPASS-4 clinical trial, which were published in The Lancet.
-
SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a possible treatment for type 2 diabetes.
-
Lilly Declares Fourth-Quarter 2021 Dividend
10/18/2021
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock.